Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | FNTB | P49356 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643824 | 0.91 | CYP1A2 (0.38) | KCNH2MCHR1LMNA | |
| SCHEMBL6479580 | 0.91 | GSK3A (0.39) | GSK3AGSK3BLMNAALDH1A1VKORC1 | |
| SCHEMBL646432 | 0.90 | GSK3A (0.37) | KCNH2MCHR1GSK3AGSK3BALDH1A1 | |
| SCHEMBL645288 | 0.89 | KCNH2 (0.44) | KCNH2MCHR1KIF11ACP1LMNA | |
| SCHEMBL644186 | 0.89 | KCNH2 (0.35) | KCNH2MCHR1KIF11ACP1LMNA | |
| SCHEMBL646466 | 0.89 | KIF11 (0.42) | KCNH2KIF11ACP1PTPN1 | |
| SCHEMBL646932 | 0.89 | CYP1A2 (0.41) | KCNH2MCHR1GSK3AGSK3BLMNA | |
| SCHEMBL644184 | 0.88 | CYP1A2 (0.45) | KCNH2MCHR1LMNAALDH1A1HPGD | |
| SCHEMBL644099 | 0.87 | KCNH2 (0.35) | KCNH2MCHR1GSK3AGSK3BKIF11 | |
| SCHEMBL644716 | 0.87 | KIF11 (0.37) | KCNH2KIF11ACP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7629477-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | KCNH2 3954/4885MCHR1 3435/4885GSK3A 2442/4885 |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | KCNH2 955/4885MCHR1 4365/4885GSK3A 610/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KCNH2 2582/4885MCHR1 4421/4885GSK3A 1458/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KCNH2 2582/4885MCHR1 4421/4885GSK3A 1458/4885 |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KCNH2 2582/4885MCHR1 4421/4885GSK3A 1458/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KCNH2 2582/4885MCHR1 4421/4885GSK3A 1458/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KCNH2 2582/4885MCHR1 4421/4885GSK3A 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.